Phase I/II Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in Canada
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04398147 |
|
Recruitment Status :
Not yet recruiting
First Posted : May 21, 2020
Last Update Posted : July 2, 2020
|
Sponsor:
CanSino Biologics Inc.
Collaborators:
Beijing Institute of Biotechnology
Canadian Center for Vaccinology
Information provided by (Responsible Party):
CanSino Biologics Inc.
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Not yet recruiting |
|---|---|
| Estimated Primary Completion Date : | December 20, 2021 |
| Estimated Study Completion Date : | December 30, 2021 |